Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.

[1]  M. Link,et al.  Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients. , 2013, Heart rhythm.

[2]  Robert G. Hauser,et al.  The subcutaneous implantable cardioverter-defibrillator: should patients want one? , 2013, Journal of the American College of Cardiology.

[3]  L. Jordaens,et al.  Outcome and Complications After Implantable Cardioverter Defibrillator Therapy in Hypertrophic Cardiomyopathy: Systematic Review and Meta-Analysis , 2012, Circulation. Heart failure.

[4]  Barry J Maron,et al.  Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. , 2012, Journal of the American College of Cardiology.

[5]  J. Till,et al.  Clinical experience of entirely subcutaneous implantable cardioverter-defibrillators in children and adults: cause for caution. , 2012, European heart journal.

[6]  Barry J Maron,et al.  2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.

[7]  Barry J Maron,et al.  2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Soci , 2011, Journal of the American College of Cardiology.

[8]  D. Horstkotte,et al.  The diagnosis and treatment of hypertrophic cardiomyopathy. , 2011, Deutsches Arzteblatt international.

[9]  B. Gersh,et al.  Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy. , 2010, The American journal of cardiology.

[10]  J. Vogt,et al.  Incidence of adequate ICD interventions in patients with hypertrophic cardiomyopathy supposed to be at high risk for sudden cardiac death , 2010, Acta cardiologica.

[11]  J. Hodges,et al.  Long-term survival after cardiac arrest in hypertrophic cardiomyopathy. , 2009, Heart rhythm.

[12]  C. Autore,et al.  Syncope and Risk of Sudden Death in Hypertrophic Cardiomyopathy , 2009, Circulation.

[13]  B. Gersh,et al.  How should hypertrophic cardiomyopathy be classified?: What's in a name? Dilemmas in nomenclature characterizing hypertrophic cardiomyopathy and left ventricular hypertrophy. , 2009, Circulation. Cardiovascular genetics.

[14]  B. Maron,et al.  Implantable Defibrillators and Prevention of Sudden Death in Hypertrophic Cardiomyopathy , 2008, Journal of cardiovascular electrophysiology.

[15]  M. Josephson,et al.  A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. , 2008, Journal of the American College of Cardiology.

[16]  Wei Du,et al.  Regression equations for calculation of z scores of cardiac structures in a large cohort of healthy infants, children, and adolescents: an echocardiographic study. , 2008, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[17]  J. Triedman,et al.  Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients. , 2008, Journal of the American College of Cardiology.

[18]  L. Harris,et al.  Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathy , 2007, Heart.

[19]  M. Link,et al.  Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. , 2007, JAMA.

[20]  P. Elliott,et al.  Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy , 2006, Heart.

[21]  W. Manning,et al.  Prevalence, Clinical Profile, and Significance of Left Ventricular Remodeling in the End-Stage Phase of Hypertrophic Cardiomyopathy , 2006, Circulation.

[22]  R. Berger,et al.  Are Implantable Cardioverter Defibrillator Shocks a Surrogate for Sudden Cardiac Death in Patients With Nonischemic Cardiomyopathy? , 2006, Circulation.

[23]  S. Connolly,et al.  Use and misuse of surrogate outcomes in arrhythmia trials. , 2006, Circulation.

[24]  Robert G. Hauser,et al.  Lessons From the Failure and Recall of an Implantable Cardioverter-Defibrillator , 2005, Circulation.

[25]  B. Maron,et al.  Introduction: eligibility recommendations for competitive athletes with cardiovascular abnormalities-general considerations. , 2005, Journal of the American College of Cardiology.

[26]  G. Boriani,et al.  Prevention of Sudden Death in Hypertrophic Cardiomyopathy: But Which Defibrillator for Which Patient? , 2004, Circulation.

[27]  T. Paul,et al.  High Incidence of Appropriate and Inappropriate ICD Therapies in Children and Adolescents with Implantable Cardioverter Defibrillator , 2004, Pacing and clinical electrophysiology : PACE.

[28]  C. Semsarian,et al.  Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy. , 2004, The American journal of cardiology.

[29]  Barry J Maron,et al.  American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G , 2003, Journal of the American College of Cardiology.

[30]  L. Fananapazir,et al.  Efficacy of Implantable Cardioverter Defibrillator Therapy for Primary and Secondary Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy , 2003, Pacing and clinical electrophysiology : PACE.

[31]  P. Elliott,et al.  Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. , 2003, Journal of the American College of Cardiology.

[32]  P. Elliott,et al.  Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. , 2000, Journal of the American College of Cardiology.

[33]  B. Maron,et al.  Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. , 2000, Circulation.

[34]  B. Maron,et al.  Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[35]  M. Link,et al.  Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[36]  F. Triposkiadis,et al.  Clinical Investigations: CardiologyHypertrophic Cardiomyopathy in Greece: Clinical Course and Outcome , 1998 .

[37]  M. Burch,et al.  Hypertrophic cardiomyopathy. , 1994, Archives of disease in childhood.

[38]  M. Bernard.  Impact of Implanted Recalled Sprint Fidelis Lead on Patient Mortality , 2012 .

[39]  J. Stockman.  Clinical Outcome and Phenotypic Expression in LAMP2 Cardiomyopathy , 2011 .

[40]  B. Maron.  Contemporary Reviews in Cardiovascular Medicine Contemporary Insights and Strategies for Risk Stratification and Prevention of Sudden Death in Hypertrophic Cardiomyopathy , 2010 .

[41]  R. Bonow,et al.  36th Bethesda Conference: Eligibility Recommendations for Competitive Athletes With Cardiovascular Abnormalities , 2005 .